Kenneth J. Valenzano
Departments of Molecular Pharmacology
Pudue Pharma Discovery Research
6 Cedarbrook Dr.
Cranbury
USA
Name/email consistency: high
- Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Valenzano, K.J., Tafesse, L., Lee, G., Harrison, J.E., Boulet, J.M., Gottshall, S.L., Mark, L., Pearson, M.S., Miller, W., Shan, S., Rabadi, L., Rotshteyn, Y., Chaffer, S.M., Turchin, P.I., Elsemore, D.A., Toth, M., Koetzner, L., Whiteside, G.T. Neuropharmacology (2005)
- DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties. Valenzano, K.J., Miller, W., Chen, Z., Shan, S., Crumley, G., Victory, S.F., Davies, E., Huang, J.C., Allie, N., Nolan, S.J., Rotshteyn, Y., Kyle, D.J., Broglé, K. J. Pharmacol. Exp. Ther. (2004)
- Current perspectives on the therapeutic utility of VR1 antagonists. Valenzano, K.J., Sun, Q. Curr. Med. Chem. (2004)
- N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. Valenzano, K.J., Grant, E.R., Wu, G., Hachicha, M., Schmid, L., Tafesse, L., Sun, Q., Rotshteyn, Y., Francis, J., Limberis, J., Malik, S., Whittemore, E.R., Hodges, D. J. Pharmacol. Exp. Ther. (2003)
